healthy subjects.
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: I. Adult male and non-menopausal female aged 20-60 year
Exclusion criteria
Exclusion criteria: I. History of type 2 diabetes I. History of coronary heart disease II. Abnormal liver function test (ALT and AST > 45 U/L ) III. Abnormal kidney function test (createnine > 1.4 mg/dL) IV. On lipid lowering medication V. Pregnancy and breast feeding VI. Female on oral contraceptive unless they have no intention to change during the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Plasma LDL-cholesterol. Timepoint: Measurements at baseline (before the start of the intervention) and 4 weeks after the start. Method of measurement: Spectrophotometry.;Plasma apo B levels. Timepoint: Measurements at baseline (before the start of the intervention) and 4 weeks after the start. Method of measurement: Spectrophotometry. | — |
Secondary
| Measure | Time frame |
|---|---|
| Plasma TG. Timepoint: Measurements at baseline and 4 weeks after each intervention. Method of measurement: Spectrophotometry.;Plasma ALT. Timepoint: Measurements at baseline and 4 weeks after each intervention. Method of measurement: Spectrophotometry.;Plasma Insulin levels. Timepoint: Measurements at baseline and 4 weeks after each intervention. Method of measurement: ELISA.;Plasma Adiponectin levels. Timepoint: Measurements at baseline and 4 weeks after each intervention. Method of measurement: ELISA. | — |
Countries
Iran (Islamic Republic of)
Contacts
Shahid Beheshti University of Medical Sciences